This phase 2 trial demonstrated that tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. With a manageable safety profile and no new safety signals identified, tarlatamab could represent a significant advancement in the treatment landscape for these patients.

The phase 3 trial showed that enzalutamide, when used as a monotherapy or in combination with leuprolide, resulted in superior metastasis-free survival rates for patients with high-risk biochemical recurrence of prostate cancer.

This study highlights an urgent need for adaptation in our healthcare systems – a 21% increase in pediatric dental emergencies during the first wave of COVID-19 underscores this point. It’s crucial that we ensure continued access to high-quality dental care for our pediatric patients, even amidst a global health crisis.

The proposed antiracism framework in dental education could be a game-changer. By addressing systemic racism and improving representation, we can ensure better patient care for all.

Did you know that mobile health applications can reduce symptoms in patients affected by obstructive sleep apnea–hypopnea syndrome (OSAHS) and improve the swallowing-related quality of life of elderly patients? This is just one of the many ways these apps are transforming oral health care.

Did you know that pre-restorative orthodontics can optimize spaces for prosthetic replacements and improve unfavorable features of the malocclusion? This breakthrough could make your practice more effective and patient-friendly.